Biogen income statement

In fiscal 2025, Biogen reported revenue of $9.89bn, up 2.2% on the year before and net income of $1.29bn, or $8.79 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biogen: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	4.4	4.7	5.0	5.5	6.9	9.7	10.8	11.4	12.3	13.5	14.4	13.4	11.0	10.2	9.8	9.7	9.9	10.3
Cost of revenue	0.4	0.4	0.5	0.5	—	—	—	1.5	1.6	1.8	2.0	1.8	2.1	2.3	2.5	2.3	2.4	2.7
Gross profit	4.0	4.3	4.6	5.0	6.1	8.5	9.5	10.0	10.6	11.6	12.4	11.6	8.9	7.9	7.3	7.4	7.5	7.6
Research and development	1.3	1.2	1.2	1.3	1.4	1.9	2.0	2.0	2.3	2.6	2.3	4.0	2.5	2.2	2.4	2.0	1.8	2.2
Selling, general and administrative	0.9	1.0	1.1	1.3	1.7	2.2	2.1	1.9	1.9	2.1	2.4	2.5	2.7	2.4	2.5	2.4	2.4	2.8
Operating income	1.3	1.2	1.7	1.9	2.5	4.0	4.9	5.2	5.3	5.9	7.0	4.6	2.8	—	—	—	—	—
Interest expense	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.3	0.2	0.2	0.2	0.3	0.2	0.2	0.3	0.3	0.3
Income before tax	1.3	1.2	1.7	1.9	2.5	3.9	4.8	4.9	5.1	5.9	7.1	5.0	1.7	3.6	1.3	1.9	1.6	0.4
Income tax	0.4	0.3	0.4	0.5	0.6	1.0	1.2	1.2	2.5	1.4	1.2	1.0	0.1	0.6	0.1	0.3	0.3	0.1
Net income	1.0	1.0	1.2	1.4	1.9	2.9	3.5	3.7	2.5	4.4	5.9	4.0	1.6	3.0	1.2	1.6	1.3	0.3
Diluted EPS	$3.35	$3.94	$5.04	$5.76	$7.81	$12.37	$15.34	$16.93	$11.92	$21.58	$31.42	$24.80	$10.40	$20.87	$7.97	$11.18	$8.79	$2.34
Diluted shares (average)	289m	255m	245m	240m	238m	237m	231m	219m	213m	205m	187m	161m	150m	146m	146m	146m	147m	148m
EBITDA	1.7	1.6	2.1	2.2	3.0	4.7	5.5	5.8	6.4	6.5	7.5	5.0	3.3	—	—	—	—	—

US$ millions unless shown otherwise. Fiscal quarters.

Biogen: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	2,455	2,431	2,646	2,535	2,279	2,478	2,736	2,804
Cost of revenue	584	629	605	674	496	661	777	748
Gross profit	1,871	1,802	2,041	1,860	1,784	1,817	1,959	2,056
Research and development	513	434	399	436	509	539	530	574
Selling, general and administrative	680	573	584	595	683	607	710	752
Interest expense	60	60	73	67	68	68	82	88
Income before tax	292	311	744	557	−56	378	132	−9
Income tax	25	71	109	91	−7	58	35	12
Net income	267	241	635	467	−49	320	98	−21
Diluted EPS	$1.83	$1.64	$4.33	$3.17	−$0.35	$2.15	$0.66	−$0.14

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BIIB vs VRTX BIIB vs REGN BIIB vs INCY

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biogen's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biogen.